BeiGene’s Mehrdad Mobasher, MD, MPH, Discusses CLL Data, Pipeline Following ASH 2024
Some time ago, officials at BeiGene started looking at data for their Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa) in years, not months. Still, sharing 5-year follow-up data for the SEQUOIA study (NCT03336333)1 at the 66th American …